Siemens Health/€SHL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Siemens Health
Siemens Healthineers AG, listed under the ticker SHL, operates in the healthcare sector and is particularly known for its innovative medical technology. The company, a segment of the larger Siemens Group, specializes in diagnostic and therapeutic products and services, including medical imaging, laboratory diagnostics, and point-of-care testing. Founded in 1847 as part of Siemens AG, Siemens Healthineers was spun off as a separate entity in 2018, reflecting its focus on healthcare technology and services.
- Ticker
- €SHL
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 74,600
- Headquarters
- Forchheim, Germany
- Website
- www.siemens-healthineers.com
Siemens Health Metrics
BasicAdvanced
€48B
21.93
€1.97
0.89
€1.00
2.32%
Price and volume
Market cap
€48B
Beta
0.89
52-week high
€47.24
52-week low
€32.84
Average daily volume
1M
Dividend rate
€1.00
Financial strength
Current ratio
1.184
Quick ratio
0.751
Long term debt to equity
0.579
Total debt to equity
0.74
Dividend payout ratio (TTM)
50.50%
Interest coverage (TTM)
7.83%
Profitability
EBITDA (TTM)
4,381
Gross margin (TTM)
38.57%
Net profit margin (TTM)
9.37%
Operating margin (TTM)
13.52%
Effective tax rate (TTM)
22.36%
Revenue per employee (TTM)
€320,000
Management effectiveness
Return on assets (TTM)
4.38%
Return on equity (TTM)
11.80%
Valuation
Price to earnings (TTM)
21.926
Price to revenue (TTM)
2.044
Price to book
2.42
Price to tangible book (TTM)
-11.69
Price to free cash flow (TTM)
19.755
Free cash flow yield (TTM)
5.06%
Free cash flow per share (TTM)
2.187
Dividend yield (TTM)
2.32%
Forward dividend yield
2.32%
Growth
Revenue change (TTM)
1.09%
Earnings per share change (TTM)
3.14%
3-year revenue growth (CAGR)
2.91%
10-year revenue growth (CAGR)
5.72%
3-year earnings per share growth (CAGR)
13.71%
10-year earnings per share growth (CAGR)
4.16%
3-year dividend per share growth (CAGR)
1.72%
What the Analysts think about Siemens Health
Analyst ratings (Buy, Hold, Sell) for Siemens Health stock.
Analyst projections of the future price of Siemens Health stock.
Bulls say / Bears say
Equipment orders outpaced sales in Q3, lifting the book-to-bill ratio to 1.27; two new US hospital partnerships also added several hundred million euros of equipment orders. That gives the company a strong order pipeline to convert into future revenue. (Siemens Healthineers, StockAnalysis)
Precision Therapy revenue grew 9.2% in Q3, making it a strong counterweight to weaker Diagnostics. The launch of the Accela radiotherapy system adds a new product to support the cancer-care business. (Siemens Healthineers, Siemens Healthineers)
Newer imaging products are gaining traction: photon-counting CT made up about 30% of CT equipment orders, while DryCool accounted for half of MRI units ordered. Wider adoption of these differentiated systems could support future Imaging growth. (StockAnalysis)
Diagnostics remains a material drag: revenue fell 5.5% in Q3 and the company cut its 2026 revenue-growth outlook to 3.5–4.0%. China’s procurement and reimbursement changes, alongside the shift away from legacy platforms, are weighing on sales. (Reuters, Siemens Healthineers)
The higher 2026 EPS forecast does not reflect a stronger underlying earnings outlook: the company said the €0.15 increase came from US tariff refunds, while its revenue-growth guidance was reduced. That makes the headline earnings upgrade less durable. (Siemens Healthineers)
Management expects normalising tax, refinancing costs and recurring separation costs to reduce FY2027 EPS by about €0.15. These additional costs could make it harder to deliver the company’s targeted earnings growth. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Siemens Health Financial Performance
Revenues and expenses
Siemens Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Siemens Health
AllEURUSDGBP
Fund name | Fund size | €SHL weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 12.19% |
iShares DivDAX€EXSB | €562M | 2.75% |
iShares Dax ESG€EXIA | €127M | 0.91% |
Xtrackers DAX£XDAX | €7.3B | 0.89% |
iShares Core DAX€EXIC | €75M | 0.89% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.